Revolutionizing Treatment for Immune-mediated Diseases

A New Paradigm in Immunotherapy

Oxion Biologics is a clinical stage company developing OX118 for use in numerous immune-mediated conditions with significant unmet needs. Our therapy offers true disease-modifying potential and an unparalleled safety profile. With worldwide IP right and phase 1 trials starting in early 2025, we're rapidly advancing toward clinical validation.